Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jul 21, 2013; 19(27): 4344-4350
Published online Jul 21, 2013. doi: 10.3748/wjg.v19.i27.4344
Published online Jul 21, 2013. doi: 10.3748/wjg.v19.i27.4344
Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: Results of a systematic review
Herma H Fidder, Maartje MJ Singendonk, Mike van der Have, Bas Oldenburg, Martijn GH van Oijen, Department of Gastroenterology and Hepatology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
Author contributions: Fidder HH, Singendonk MMJ and van Oijen MGH contributed equally to this work and designed and performed the research and wrote the paper, van der Have M and Oldenburg B contributed to the writing process.
Correspondence to: Herma H Fidder, MD, PhD, Department of Gastroenterology and Hepatology, University Medical Center Utrecht, PO Box 85500 (internal code F02.618), 3508 GA Utrecht, The Netherlands. h.fidder@umcutrecht.nl
Telephone: +31-88-7557325 Fax: +31-88-7555533
Received: December 24, 2012
Revised: February 12, 2013
Accepted: March 21, 2013
Published online: July 21, 2013
Revised: February 12, 2013
Accepted: March 21, 2013
Published online: July 21, 2013
Core Tip
Core tip: This study assessed adherence with tumor necrosis factor-α (TNF-α) inhibitors in Crohn’s disease (CD) and rheumatoid arthritis (RA) by systematic review. We found only two-third of the patients with CD and RA receiving TNF-α inhibitors adherent to therapy. Definitions of measurement of adherence varied widely between studies and there is no clarity on what levels of adherence are required for optimal results of therapy. Future research on adherence should focus on therapy outcome, by using uniform definitions of adherence.